Use of Paclitaxel in ovarian cancer is justified
The congratulations offered by Dr Harding to those health authorities yet to make Paclitaxel available to their patients with ovarian cancer are misplaced. The evidence was summarised in Effective Health Care and is set out more fully in the research evidence volume of the Guidance on Commissioning Cancer Services - ...
You need to be an HSJ subscriber to read more
Subscribe to read the full article
With an HSJ subscription you’ll get access to:
- Expert Briefing newsletters, covering nine topics and regions
- Weekly Catch Up – a summary of the week’s most important stories
- Unlimited access to hsj.co.uk
- The HSJ app
Enquire about multi-user access